{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:52:57Z","timestamp":1790419977664,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Mucopolysaccharidosis type VII (Sly disease, MPS VII), is an ultra-rare, multi-symptom disease with variable clinical presentations which can present challenges with diagnosis, management and care. We believe this survey is the first to explore the patient experience through direct questioning of the caregivers of 13 individuals with MPS VII.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This European survey, using a specifically designed questionnaire, was conducted in order to describe the pathway to diagnosis and the burden of illness of MPS VII. Information on early symptoms, clinicians seen, and current symptoms was collected. Questions on the caregivers\u2019 ability to work and the use and availability of health, social and educational support were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Caregivers of 13 patients from Germany, Spain, The Netherlands and Turkey responded to the survey. Five patients with non-immune hydrops fetalis (NIHF) were diagnosed with MPS VII at a mean age of 1.9\u2009years (median 0.3\u2009years, range 0.2 to 6\u2009years). Those without NIHF (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u20097) were diagnosed at a mean age of 6.1\u2009years (median 6.0\u2009years, range 1.9 to 14\u2009years). The symptoms most likely to raise a suspicion of MPS VII, excluding NIHF, did not appear until a median age of at least three years.\n                    <\/jats:p>\n                    <jats:p>Over one half of patients required assistance with daily living and mobility. Reduction of the working hours of caregivers was often necessary (46.2% reduced hours, 30.8% stopped working).<\/jats:p>\n                    <jats:p>Patients attended frequent medical appointments (12.7\/year), over 80% had surgery and 30% had been hospitalised for respiratory issues.<\/jats:p>\n                    <jats:p>While support for learning and behavioural needs was generally available, support for mobility was not available to 50% of patients. Half of the respondents (6\/12) said they were not offered genetic counselling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For children that do not present with NIHF, diagnosis can take several years as early symptoms can be non-specific and mistaken for other conditions. Increased awareness of the early signs of disease and more information for parents\/caregivers at diagnosis are needed. MPS VII poses significant burden to patients, caregivers, healthcare, social and educational services. Access to information and support varies across Europe and the availability of genetic counselling is limited in some countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-019-1233-z","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T07:02:32Z","timestamp":1573714952000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII \u2013 a European caregiver survey"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3525-5030","authenticated-orcid":false,"given":"Alexandra","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmee","family":"Oussoren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Friedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalan","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"issue":"6","key":"1233_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","volume":"53","author":"AM Monta\u00f1o","year":"2016","unstructured":"Monta\u00f1o AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53(6):403\u201318.","journal-title":"J Med Genet"},{"issue":"2","key":"1233_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","volume":"82","author":"WS Sly","year":"1973","unstructured":"Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr. 1973;82(2):249\u201357.","journal-title":"J Pediatr"},{"key":"1233_CR3","unstructured":"MPS Society. Guide to Understanding Mucopolysaccharidosis VII (MPS VII) Sly. Amersham: MPS Society; 2013."},{"key":"1233_CR4","unstructured":"Orphanet: Mucopolysaccharidosis type 7. https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php? Expert=584. Accessed 20 March 2019."},{"issue":"9","key":"1233_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/gim.2017.10","volume":"19","author":"M Zielonka","year":"2017","unstructured":"Zielonka M, Garbade SF, K\u00f6lker S, Hoffmann GF, Ries M. Quantitative clinical characteristics of 53 patients with MPS VII: a cross-sectional analysis. Genet Med. 2017;19(9):983\u20138.","journal-title":"Genet Med"},{"key":"1233_CR6","unstructured":"National Organisation for Rare Disorders (NORD) - Mucopolysaccharidosis Type VII. https:\/\/rarediseases.org\/rare-diseases\/sly-syndrome\/. Accessed 20 March 2019."},{"key":"1233_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ymgme.2017.09.010","volume":"122S","author":"ML Escolar","year":"2017","unstructured":"Escolar ML, Jones SA, Shapiro EG, Horovitz DDG, Lampe C, Amartino H. Practical management of behavioral problems in mucopolysaccharidoses disorders. Mol Genet Metab. 2017;122S:35\u201340.","journal-title":"Mol Genet Metab"},{"key":"1233_CR8","unstructured":"The UK Strategy for Rare Diseases. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/260562\/UK_Strategy_for_Rare_Diseases.pdf. Accessed 20 March 2019."},{"issue":"1\u20132","key":"1233_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ymgme.2013.06.007","volume":"110","author":"S Tomatsu","year":"2013","unstructured":"Tomatsu S, Fujii T, Fukushi M, Oguma T, Shimada T, Maeda M, et al. Newborn screening and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2013;110(1\u20132):42\u201353.","journal-title":"Mol Genet Metab"},{"issue":"Suppl 5","key":"1233_CR10","doi-asserted-by":"publisher","first-page":"v41","DOI":"10.1093\/rheumatology\/ker390","volume":"50","author":"TJ Lehman","year":"2011","unstructured":"Lehman TJ, Miller N, Norquist B, Underhill L, Keutzer J. Diagnosis of the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v41\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"1233_CR11","unstructured":"MPS Society - MPS VII Sly Disease. http:\/\/www.mpssociety.org.uk\/diseases\/mps-diseases\/mps-vii\/. Accessed 20 March 2019."},{"issue":"11","key":"1233_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/pd.4663","volume":"35","author":"J Verma","year":"2015","unstructured":"Verma J, Thomas DC, Sharma S, Jhingan G, Saxena R, Kohli S, et al. Inherited metabolic disorders: prenatal diagnosis of lysosomal storage disorders. Prenat Diagn. 2015;35(11):1137\u201347.","journal-title":"Prenat Diagn"},{"issue":"1\u20132","key":"1233_CR13","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2018.01.003","volume":"125","author":"M Stapleton","year":"2018","unstructured":"Stapleton M, Arunkumar N, Kubaski F, Mason RW, Tadao O, Tomatsu S. Clinical presentation and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2018;125(1\u20132):4\u201317.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"1233_CR14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/pd.3972","volume":"32","author":"L Gort","year":"2012","unstructured":"Gort L, Granell MR, Fern\u00e1ndez G, Carreto P, Sanchez A, Coll MJ. Fast protocol for the diagnosis of lysosomal diseases in nonimmune hydrops fetalis. Prenat Diagn. 2012;32(12):1139\u201342.","journal-title":"Prenat Diagn"},{"issue":"6","key":"1233_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/sj.bmt.1701141","volume":"21","author":"Y Yamada","year":"1998","unstructured":"Yamada Y, Kato K, Sukegawa K, Tomatsu S, Fukuda S, Emura S, et al. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant. 1998;21(6):629\u201334.","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"1233_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/petr.13278","volume":"22","author":"L Sisinni","year":"2018","unstructured":"Sisinni L, Pineda M, Coll MJ, Gort L, Turon E, Torrent M, et al. Haematopoietic stem cell transplantation for mucopolysaccharidosis type VII: a case report. Pediatr Transplant. 2018;22(7):e13278.","journal-title":"Pediatr Transplant"},{"key":"1233_CR17","unstructured":"Ultragenyx Announces FDA Approval of MEPSEVII\u2122 (vestronidase alfa), the First Therapy for Progressive and Debilitating Rare Genetic Disease Mucopolysaccharidosis VII. http:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-announces-fda-approval-mepseviitm-vestronidase-alfa. Accessed 20 March 2019."},{"key":"1233_CR18","unstructured":"Ultragenyx Announces Approval of Mepsevii\u2122 (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII. http:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-announces-approval-mepseviitm-vestronidase-alfa. Accessed 20 March 2019."},{"key":"1233_CR19","unstructured":"Ultragenyx Announces Approval of Mepsevii\u2122 (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII. http:\/\/ir.ultragenyx.com\/news-releases\/news-release-details\/ultragenyx-announces-approval-mepseviitm-vestronidase-alfa-0. Accessed 20 March 2019."},{"issue":"4","key":"1233_CR20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","volume":"123","author":"P Harmatz","year":"2018","unstructured":"Harmatz P, Whitley CB, Wang RY, Bauer M, Song W, Haller C, et al. A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488\u201394.","journal-title":"Mol Genet Metab"},{"key":"1233_CR21","unstructured":"MPS Society. A guide to understanding MPS VII. 2008. https:\/\/mpssociety.org\/cms\/wp-content\/uploads\/2017\/04\/MPS_VII_2008.pdf. Accessed 20 March 2019."},{"issue":"Suppl 5","key":"1233_CR22","doi-asserted-by":"publisher","first-page":"v26","DOI":"10.1093\/rheumatology\/ker393","volume":"50","author":"KK White","year":"2011","unstructured":"White KK. Orthopaedic aspects of mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v26\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 1","key":"1233_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10198-016-0787-0","volume":"17","author":"M P\u00e9ntek","year":"2016","unstructured":"P\u00e9ntek M, Gul\u00e1csi L, Brodszky V, Baji P, Boncz I, Pog\u00e1ny G, et al. Social\/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe. Eur J Health Econ. 2016;17(Suppl 1):89\u201398.","journal-title":"Eur J Health Econ"},{"key":"1233_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgmr.2016.05.006","volume":"8","author":"ET Rush","year":"2016","unstructured":"Rush ET. Atypical presentation of mucopolysaccharidosis type IVA. Mol Genet Metab Rep. 2016;8:8\u201312.","journal-title":"Mol Genet Metab Rep"},{"issue":"2","key":"1233_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ajog.2014.12.018","volume":"212","author":"ME Norton","year":"2015","unstructured":"Norton ME, Chauhan SP, Dashe JS. (SMFM) SfM-FM. Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015;212(2):127\u201339.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"1233_CR26","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ajog.2014.10.007","volume":"212","author":"AC Gimovsky","year":"2015","unstructured":"Gimovsky AC, Luzi P, Berghella V. Lysosomal storage disease as an etiology of nonimmune hydrops. Am J Obstet Gynecol. 2015;212(3):281\u201390.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"1233_CR27","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/ajmg.a.36988","volume":"167A","author":"C Bellini","year":"2015","unstructured":"Bellini C, Donarini G, Paladini D, Calevo MG, Bellini T, Ramenghi LA, et al. Etiology of non-immune hydrops fetalis: an update. Am J Med Genet A. 2015;167A(5):1082\u20138.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"1233_CR28","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s10545-016-9947-8","volume":"39","author":"C Vianey-Saban","year":"2016","unstructured":"Vianey-Saban C, Acquaviva C, Cheillan D, Collardeau-Frachon S, Guibaud L, Pagan C, et al. Antenatal manifestations of inborn errors of metabolism: biological diagnosis. J Inherit Metab Dis. 2016;39(5):611\u201324.","journal-title":"J Inherit Metab Dis"},{"key":"1233_CR29","unstructured":"MPS VII in focus. http:\/\/mpsviiinfocus.com\/resources\/. Accessed 20 March 2019."},{"issue":"9","key":"1233_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1651-2227.2012.02680.x","volume":"101","author":"C Malcolm","year":"2012","unstructured":"Malcolm C, Hain R, Gibson F, Adams S, Anderson G, Forbat L. Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families. Acta Paediatr. 2012;101(9):985\u201392.","journal-title":"Acta Paediatr"},{"issue":"1","key":"1233_CR31","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13023-019-1150-1","volume":"14","author":"E Shapiro","year":"2019","unstructured":"Shapiro E, Louren\u00e7o CM, Mungan NO, Muschol N, O'Neill C, Vijayaraghavan S. Analysis of the caregiver burden associated with Sanfilippo syndrome type B: panel recommendations based on qualitative and quantitative data. Orphanet J Rare Dis. 2019;14(1):168.","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"1233_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","volume":"11","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, et al. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet J Rare Dis. 2016;11(1):119.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1233_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13104-018-3157-4","volume":"11","author":"MR Oliveira","year":"2018","unstructured":"Oliveira MR, Schwartz I, Costa LS, Maia H, Ribeiro M, Guerreiro LB, et al. Quality of life in mucopolysaccharidoses: construction of a specific measure using the focus group technique. BMC Res Notes. 2018;11(1):28.","journal-title":"BMC Res Notes"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1233-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1233-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T19:28:15Z","timestamp":1605209295000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1233-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1233-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"22 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethics approval was necessary for this study.Informed consent was obtained from all participants. Participant Information Sheets and Consent Forms were translated into local language.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AM declares that she has no competing interests. TF declares that she has no competing interests. JC declares that he has no competing interests. NY declares that she has no competing interests. EO participated in an advisory board for Ultragenyx.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}